A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells

Drug Discovery Today

Volumn 20, Issue 1, 2015, Pages 37-49

  Giri, Shibashish ^a   Bader, Augustinus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; DRUG;

COST; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG QUALITY; ETHNIC GROUP; GENETIC POLYMORPHISM; HUMAN; IN VIVO STUDY; LABORATORY; MICROENVIRONMENT; NONHUMAN; PLURIPOTENT STEM CELL; PREDICTION; REVIEW; RISK FACTOR; ANIMAL; ECONOMICS; METABOLISM; POSTMARKETING SURVEILLANCE; PROCEDURES;

ANIMALS; COSTS AND COST ANALYSIS; DRUG DISCOVERY; ETHNIC GROUPS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84921511195     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.10.011     Document Type: Review

References (110)

1. Paul, S.M. et al. (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214
2. Baras, A.I. et al. (2012) Drug development risk and the cost of capital. Nat. Rev. Drug Discov. 11, 347-348
3. Mullard, A. (2014) FDA drug approvals. Nat. Rev. Drug Discov. 13, 85-89
4. Macleod, M. (2005) What can systematic review and meta-analysis tell us about the experimental data supporting stroke drug development? Int J. Neuroprot. Neuroregener. 1, 201
5. Akhtar, A., ed. (2012) Why Treating Animals Better is Critical to Human Welfare, Palgrave Macmillan
6. Bailey, J. (2008) An assessment of the role of chimpanzees in AIDS vaccine research. Altern. Lab. Anim. 36, 381-428
7. Nutt, D. and Goodwin, G. (2011) ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur. Neuropsychopharmacol. 21, 495-499
8. Rice, J. (2012) Animal models: not close enough. Nature 484, S9
9. Seok, J. et al. (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110, 3507-3512
10. TeGenero Immunotherapeutics (2005) Investigator's Brochure: TGN1412: Humanized Agonistic Anti-CD28 Monoclonal Antibody. TeGenero AG
11. Kenter, M.J.H. and Cohen, A.F. (2006) Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368, 1387-1391
12. Marshall, E. (2006) Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311, 1688-1689
13. Guntharalingam, G. et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028
14. Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676
15. Evans, M.J. and Kaufman, M.H. (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154-156
16. Gurdon, J.B. et al. (1958) Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 182, 64-65
17. Abyzov, A. et al. (2012) Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 492, 438-442
18. Zimmerman, H. (1999) Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd edn), Lippincott, Williams & Wilkins
19. Minotti, G., ed. (2010) Cardiotoxicity of Non-Cardiovascular Drugs, John Wiley & Sons
20. Dykens, J.A. and Will, Y. (2007) The significance of mitochondrial toxicity testing. Drug Discov. Today 12, 777-785
21. Mol, P.G. et al. (2013) Post-approval safety issues with innovative drugs: a European cohort study. Drug Saf. 36, 1105-1115
22. Outterson, K. et al. (2013) Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J. Law Med. Ethics 41, 688-696
23. Anon. (2011) New drugs and indications in 2010: inadequate assessment; patients at risk. Prescrire Int. 20, 105-107 109-110
24. Qureshi, Z.P. et al. (2011) Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol. Drug Saf. 20, 772-777
25. Shah, R.R. et al. (2013) Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 36, 491-503
26. Overman, R.A. et al. (2013) Salmon calcitonin use and associated cancer risk. Ann. Pharmacother. 47, 1675-1684
27. Bramness, J.G. et al. (2012) Effect of the market withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin. Pharmacol. Ther. 91, 438-441
28. Singh, S. et al. (2013) Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern. Med. 25, 1-6
29. Hampton, L.M. et al. (2013) Cough and cold medication adverse events after market withdrawal and labeling revision. Pediatrics 132, 1047-1054
30. Cortes, J.E. et al. (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 369, 1783-1796
31. Asconape, J.J. (2014) Use of antiepileptic drugs in hepatic and renal disease. Handb. Clin. Neurol. 119, 417-432
32. Daniel, E. et al. (2014) Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 21, 656-666
33. Nevin, R.L. (2012) Limitations of postmarketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure. Clin. Infect. Dis. 55, 1167-1168 author reply 1168-1169
34. Faillie, J.L. et al. (2014) Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 51, 491-497
35. Mitka, M. (2013) FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA 310, 1664
36. Drews, J. (2000) Drug discovery: a historical perspective. Science 287, 1960-1964
37. Subramaniam, S. and Dugar, S. (2012) Outsourcing drug discovery to India and China: from surviving to thriving. Drug Discov. Today 17, 1055-1058
38. Maiti, R. and Raghavendra, M. (2007) Clinical trials in India. Pharmacol. Res. 56, 1-10
39. Padma, T.V. (2005) India's drug tests. Nature 436, 485
40. Gupta, Y.K. and Padhy, B.M. (2011) India's growing participation in global clinical trials. Trends Pharmacol. Sci. 32, 327-329
41. Hanauer, S.B. (2009) Outsourcing clinical trials. Nat. Rev. Gastroenterol. Hepatol. 6, 191
42. US Food and Drug Administration (2007) Carbamazepine Prescribing Information to Include Recommendation of Genetic Test for Patients with Asian Ancestry. FDA
43. Dietrich, M.O. and Horvath, T.L. (2012) Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 11, 675-691
44. Becker, G.J. and Hewitson, T.D. (2013) Animal models of chronic kidney disease: useful but not perfect. Nephrol. Dial. Transplant. 28, 2432-2438
45. Cheval, L. et al. (2012) Of mice and men: divergence of gene expression patterns in kidney. PLoS ONE 7, e46876
46. Brehm, M.A. et al. (2013) Overcoming current limitations in humanized mouse research. J. Infect. Dis. 208 (Suppl. 2), S125-S130
47. Lieu, C.H. et al. (2013) From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J. Natl. Cancer Inst. 105, 1441-1456
48. Bugelski, P.J. and Martin, P.L. (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br. J. Pharmacol. 166, 823-846
49. Macrae, I.M. (2011) Preclinical stroke research - advantages and disadvantages of the most common rodent models of focal ischaemia. Br. J. Pharmacol. 164, 1062-1078
50. Pirmohamed, M. et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329, 15-19
51. (2012) Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214
52. Albini, A. et al. (2010) Cardiotoxicity of anticancer drugs: the need for cardiooncology and cardio-oncological prevention. J. Natl. Cancer Inst. 102, 14-25
53. Adão, R. et al. (2013) Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev. Port. Cardiol. 32, 395-409
54. Huh, D. et al. (2012) A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci. Transl. Med. 4, 159ra147
55. Lan, F. et al. (2013) Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101-113
56. Grskovic, M. et al. (2011) Induced pluripotent stem cells - opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 10, 915-929
57. Bellin, M. et al. (2012) Induced pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell. Biol. 13, 713-726
58. Brennand, K.J. (2013) inducing cellular aging: enabling neurodegeneration-in-adish. Cell Stem Cell 13, 635-636
59. Saha, K. and Jaenisch, R. (2009) Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5, 584-595
60. Sun, N. et al. (2012) Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147
61. Gandre-Babbe, S. et al. (2013) Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood 121, 4925-4929
62. Chung, C.Y. et al. (2013) Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 342, 983-987
63. Garcon, L. et al. (2013) Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood 122, 912-921
64. Freedman, B.S. et al. (2013) Reduced ciliary polycystin-2 in induced pluripotent stem cells from polycystic kidney disease patients with PKD1 mutations. J. Am. Soc. Nephrol. 24, 1571-1586
65. Suzuki, T. et al. (2014) Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am. J. Respir. Crit. Care Med. 189, 183-193
66. Lachmann, N. et al. (2013) Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 189, 167-182
67. Blade, C.C. et al. (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11, 603-619
68. Holzheimer, R.G. and Mannick, J.A. (2001) Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt
69. Rhoades, R. and Bell, D.R. (2013) Medical Physiology: Principles for Clinical Medicine (4th edn), Wolters Kluwer Health/Lippincott Williams & Wilkins
70. Narayanan, M. et al. (2013) Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation 95, 566-572
71. Lindh, J.D. et al. (2009) Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65, 365-375
72. Burridge, S. (2013) Target watch: drugging the epigenome. Nat. Rev. Drug Discov. 12, 92-93
73. Arrowsmith, C.H. et al. (2012) Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400
74. Plenge, R.M. et al. (2013) Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581-594
75. Kamb, A. et al. (2013) Human genetics as a foundation for innovative drug development. Nat. Biotechnol. 31, 975-978
76. Johansson, I. and Ingelman-Sundberg, M. (2011) Genetic polymorphism and toxicology - with emphasis on cytochrome p450. Toxicol. Sci. 120, 1-13
77. Tod, M. et al. (2013) Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J. 15, 1242-1252
78. Alfirevic, A. et al. (2006) HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818
79. McCormack, M. et al. (2011) HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134-1143
80. Chen, P. et al. (2011) Carbamazepine-induced toxic effects and HLA-B∗1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133
81. Hung, S.I. et al. (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306
82. Tassaneeyakul, W. et al. (2010) Association between HLA-B∗1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51, 926-930
83. Garcia-Roca, P. et al. (2012) CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. Arch. Med. Res. 43, 283-287
84. Aithal, G.P. et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719
85. Sychev, D.V. et al. (2012) CYP2C9 and VKORC1 gene polymorphism is inessential for bleeding development under conditions of oral application of anticoagulant acenocoumarol in Russian patients at high risk of thromboembolic complications. Bull. Exp. Biol. Med. 153, 886-888
86. Limdi, N.A. et al. (2008) Influence of CYP2C9 and VKORC1 1173 C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321
87. Klein, T.E. et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764
88. Rost, S. et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541
89. Lam, M.P. and Cheung, B.M. (2012) The pharmacogenetics of the response to warfarin in Chinese. Br. J. Clin. Pharmacol. 73, 340-347
90. Diaz-Molina, B. et al. (2012) Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant. Proc. 44, 2635-2638
91. Torio, A. et al. (2012) Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. Transplant. Proc. 44, 2596-2598
92. Shi, Y. et al. (2013) Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene 512, 226-231
93. Gijsen, V.M. et al. (2012) Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann. Transplant. 17, 111-121
94. Mirosevic Skvrce, N. et al. (2013) CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics 14, 1419-1431
95. Sy, S.K. et al. (2013) A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS J. 15, 1189-1199
96. Laftavi, M.R. et al. (2013) African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? Transplant. Proc. 45, 3498-3501
97. Elmachad, M. et al. (2012) Frequencies of CYP3A5∗1/∗3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients. Genet. Test. Mol. Biomarkers 16, 644-647
98. Huh, P. et al. (2013) Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 341, 651-654
99. Cyranoski, D. (2012) Stem-cell pioneer banks on future therapies. Nature 488, 139
100. Turner, M. et al. (2013) Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13, 382-384
101. Gourraud, P.A. et al. (2012) The role of human leukocyte antigen matching in the development of multiethnic 'haplobank' of induced pluripotent stem cell lines. Stem Cells 30, 180-186
102. Taylor, C.J. et al. (2012) Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 11, 147-152
103. Ye, Z. et al. (2009) Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 114, 5473-5480
104. Egawa, N. et al. (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 4, 145ra104
105. Trilck, M. et al. (2013) Niemann-Pick type C1 patient-specific induced pluripotent stem cells display disease specific hallmarks. Orphanet. J. Rare Dis. 8, 144
106. Pentchev, P.G. et al. (1980) A lysosomal storage disorder in mice characterized by the accumulation of several sphingolipids. Birth Defects Orig. Artic. Ser. 16, 225-230
107. Walkley, S.U. and Suzuki, K. (2004) Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim. Biophys. Acta 1685, 48-62
108. Ordonez, M.P. et al. (2012) Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1. Hum. Mol. Genet. 21, 2651-2662
109. Matsumoto, Y. et al. (2013) Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet. J. Rare Dis. 8, 190
110. Bershteyn, M. et al. (2014) Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature http://dx.doi.org/10.1038/nature12923